Cargando…

MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model

MALDI‐MS Imaging is a novel label‐free technique that can be used to visualize the changes in multiple mass responses following treatment. Following treatment with proinflammatory cytokine interleukin‐22 (IL‐22), the epidermal differentiation of Labskin, a living skin equivalent (LSE), successfully...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, Amanda, Cole, Laura M., Day, Rebecca, Bartlett, Maggie, Warwick, John, Bojar, Richard, Smith, David, Cross, Neil, Clench, Malcolm R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094548/
https://www.ncbi.nlm.nih.gov/pubmed/27226230
http://dx.doi.org/10.1002/pmic.201600036
_version_ 1782465123836755968
author Harvey, Amanda
Cole, Laura M.
Day, Rebecca
Bartlett, Maggie
Warwick, John
Bojar, Richard
Smith, David
Cross, Neil
Clench, Malcolm R.
author_facet Harvey, Amanda
Cole, Laura M.
Day, Rebecca
Bartlett, Maggie
Warwick, John
Bojar, Richard
Smith, David
Cross, Neil
Clench, Malcolm R.
author_sort Harvey, Amanda
collection PubMed
description MALDI‐MS Imaging is a novel label‐free technique that can be used to visualize the changes in multiple mass responses following treatment. Following treatment with proinflammatory cytokine interleukin‐22 (IL‐22), the epidermal differentiation of Labskin, a living skin equivalent (LSE), successfully modeled psoriasis in vitro. Masson's trichrome staining enabled visualization and quantification of epidermal differentiation between the untreated and IL‐22 treated psoriatic LSEs. Matrix‐assisted laser desorption ionization mass spectrometry imaging was used to observe the spatial location of the psoriatic therapy drug acetretin following 48 h treatments within both psoriatic and normal LSEs. After 24 h, the drug was primarily located in the epidermal regions of both the psoriatic and nonpsoriatic LSE models whereas after 48 h it was detectible in the dermis.
format Online
Article
Text
id pubmed-5094548
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50945482016-11-09 MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model Harvey, Amanda Cole, Laura M. Day, Rebecca Bartlett, Maggie Warwick, John Bojar, Richard Smith, David Cross, Neil Clench, Malcolm R. Proteomics Technology MALDI‐MS Imaging is a novel label‐free technique that can be used to visualize the changes in multiple mass responses following treatment. Following treatment with proinflammatory cytokine interleukin‐22 (IL‐22), the epidermal differentiation of Labskin, a living skin equivalent (LSE), successfully modeled psoriasis in vitro. Masson's trichrome staining enabled visualization and quantification of epidermal differentiation between the untreated and IL‐22 treated psoriatic LSEs. Matrix‐assisted laser desorption ionization mass spectrometry imaging was used to observe the spatial location of the psoriatic therapy drug acetretin following 48 h treatments within both psoriatic and normal LSEs. After 24 h, the drug was primarily located in the epidermal regions of both the psoriatic and nonpsoriatic LSE models whereas after 48 h it was detectible in the dermis. John Wiley and Sons Inc. 2016-06-15 2016-06 /pmc/articles/PMC5094548/ /pubmed/27226230 http://dx.doi.org/10.1002/pmic.201600036 Text en © 2016 The Authors. Proteomics Published by Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Technology
Harvey, Amanda
Cole, Laura M.
Day, Rebecca
Bartlett, Maggie
Warwick, John
Bojar, Richard
Smith, David
Cross, Neil
Clench, Malcolm R.
MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model
title MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model
title_full MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model
title_fullStr MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model
title_full_unstemmed MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model
title_short MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model
title_sort maldi‐msi for the analysis of a 3d tissue‐engineered psoriatic skin model
topic Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094548/
https://www.ncbi.nlm.nih.gov/pubmed/27226230
http://dx.doi.org/10.1002/pmic.201600036
work_keys_str_mv AT harveyamanda maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT colelauram maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT dayrebecca maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT bartlettmaggie maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT warwickjohn maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT bojarrichard maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT smithdavid maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT crossneil maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel
AT clenchmalcolmr maldimsifortheanalysisofa3dtissueengineeredpsoriaticskinmodel